The x-ray structure of the unactivated kinase domain of insulin-like growth factor-1 receptor (IGFRK-0P) is reported here at 2.7Å resolution. IGFRK-0P is composed of two lobes connected by a hinge region. The N-terminal lobe of the kinase is a twisted β-sheet flanked by a single helix, and the C-terminal lobe comprises eight α-helices and four short β-strands. The ATP binding pocket and the catalytic center reside at the interface of the two lobes. Despite the overall similarity to other receptor tyrosine kinases, three notable conformational modifications are observed -1. This kinase adopts a more closed structure, with its two lobes rotated further towards each other; 2. The conformation of the proximal end of the activation loop (residues 1121 to 1129) is different; 3. The orientation of the nucleotide-binding loop is altered. Collectively, these alterations lead to a different ATP-binding pocket that might impact on inhibitor designs for IGFRK-0P. Two molecules of IGFRK-0P are seen in the asymmetric unit; they are associated as a dimer with their ATP binding clefts facing each other. The ordered N-terminus of one monomer approaches the active site of the other, suggesting that the juxta-membrane region of one molecule could come into close proximity of the active site of the other. 
The insulin-like growth factor 1 receptor (IGF-1R) 2 is a member of the transmembrane receptor tyrosine kinase superfamily. This receptor has been suggested to play important roles in cell division, development, and metabolism (1, 2) . IGF-1R is activated upon binding of the growth factors IGF-1 and IGF-2. In the activated state, IGF-1R has been implicated to play a role in oncogenesis and suppression of apoptosis (3, 4) . In a number of cancer cell lines, IGF-1R is over-expressed. In contrast, downregulation of IGF-1R expression has been shown to result in inhibition of tumorigenesis and an increased apoptosis of tumor cells (5) (6) (7) (8) (9) (10) (11) (12) . The apparent correlation between inhibition of IGF-1R activity and of tumor regression renders IGF-1R a plausible target for the development of anti-cancer drugs (13) .
IGF-1R is a hetero-tetrameric molecule, consisting of two pairs of polypeptide chains-the α-and β-chains-that are linked by disulfide bonds (14, 15) . The α-chains are extracellular and provide a binding site for the growth factors, whereas the β-chains consist of a short extracellular region, a transmembrane region, an intracellular tyrosine kinase domain, and a C-terminal tail (16) . Upon binding of IGF-1 or IGF-2, IGF-1R undergoes conformational changes with concomitant trans phosphorylation of three conserved tyrosine residues on the activation-loop of the tyrosine kinase domain (17) (18) (19) . The activated kinase facilitates phosphorylation of downstream kinase substrates. In vitro, the activated (activation-loop phosphorylated) form of the IGF-1R kinase domain readily catalyzes phosphorylation of specific tyrosine residues on peptide substrates with a rate constant about 300-fold higher than that of its unactivated counterpart. Thus, inhibition of IGF-1R activation is a plausible means to inhibiting the receptor activity.
IGF-1R shares structural similarities with another member of the receptor tyrosine kinase family -the insulin receptor (IR). IR regulates the metabolism of glycogen and fat (20) . Despite the different functional roles between these receptors, the tyrosine kinase domains of IGF-1R and IR share 84% sequence identity (21, 22) . Crystal structures of IR tyrosine kinase domain (IRK) are known for the unactivated (IRK-0P) (23) , activated (IRK-3P) (24) , and site-specifically altered (D1161A) (25) forms of the enzyme. Recently, the crystal structures of IGF-1R kinase domain have been determined in the bis-phosphorylated (IGFRK-2P) (26) and tris-phosphorylated (IGFRK-3P) (27) states. Overall, both the IGFRK-2P and -3P structures are similar to the structure of IRK-3P, suggesting that the structure of the unactivated IGF-1R kinase domain (IGFRK-0P) is likely to be similar to that of the unactivated IRK-0P.
Here, we report the crystal structure of a 321-residue, apo form of IGFRK-0P. A comparison of this structure with those of IRK-0P and IGFRK-3P reveals interesting conformational differences that may lead to differential 2 The abbreviations used are: bis-phosphorylated kinase, 2P; insulin-like growth factor 1 receptor, IGF-1R; insulin-like growth factor 1 receptor kinase, IGFK; insulin receptor, IR; insulin receptor kinase, IRK; nucleotidebinding loop, P-loop; tris-phosphorylated kinase, 3P; unactivated kinase, 0P.
inhibitor binding. These differences could be crucial for designs of specific inhibitors. Enzyme purification. Insect cell pellets (50 g from 5 liters of culture) were lysed with a dounce homogenizer in 185 ml buffer containing 25 mM Tris-HCl at pH 7.5, 10% glycerol, 5 mM 2-mercaptoethanol, 0.01% sodium azide, and a protease inhibitor cocktail (4 tablets of "Complete" from Roche Diagnostics Gmbh). Lysates were centrifuged at 30,000 rpm for 40 min in a Beckman Ti45 rotor. Column chromatography was performed with Pharmacia resins: (1) Q-Sepharose Fast Flow prepared in 25 mM TrisHCl at pH 7.5 with 10% glycerol, 5 mM 2-mercaptoethanol, 0.01% sodium azide, and eluted with 0-1 M NaCl gradient; (2) Phenyl-Sepharose HP prepared in 50 mM Tris-HCl at pH 7.5 containing 0.25 M NaCl, 20% ammonium sulfate (113 g/L), 5 mM 2-mercaptoethanol, 0.01% sodium azide, and eluted with decreasing ammonium sulfate gradient (20%-0%); (3) Superdex 200, prepared and eluted with 20 mM Tris-HCl, pH 7.5 containing 5 mM DTT. Prior to the Phenyl-Sepharose chromatography, ammonium sulfate (Fisher Biotech) was added to the Q-Sepharose pool to a final concentration of 20% in the mixture, then left on ice for 30 minutes and clarified by centrifugation at 20,000×g for 15 minutes in a Beckman JA-20 rotor. Pooled fractions from the PhenylSepharose elution were concentrated to less than 3 mL prior to the Superdex gel filtration column with Millipore Centriprep YM-10 concentrators. N-terminal sequencing indicated a blocked N-terminus. Electrospray ionization mass spectrometry was consistent with the planned primary structure that included an N-terminal acetyl group and initiator methionine. The mass calculated based on the sequence was 36605, compared to 36645 obtained by mass spectrophotometry. Addition of an acetyl group at the N-terminus would add on 42 daltons, bringing the predicted and observed mass within 2 daltons. Data collection. Crystals were harvested into a solution containing the mother liquor and 20% glycerol. The crystals were left to sit for 5 minutes prior to flash-cooling in liquid nitrogen. The crystals were transferred onto the goniostat, which was bathed in a liquid nitrogen stream. Xray diffraction data were recorded on an ADSC Quantum4 detector at the ID17 beam line of IMCA at the Advanced Photon Source, Chicago. The IGFRK-0P crystals diffracted x-rays to 2.7Å resolution. The crystals belonged to the P2 1 space group with a unit cell volume consistent with two kinase molecules per asymmetric unit. The solvent content of the crystals was 52% assuming a partial specific volume of 0.74 cm/g. The data were processed using HKL2000 (28) . Diffraction data and refinement statistics are given in Table 1 . Structure determination and refinement. The structure of IGFRK-0P was determined with the molecular replacement method using the program AMoRe (29, 30) . Model buildings were performed using X-BUILD option in program suite QUANTA (Molecular Simulations Inc., San Diego).
Materials and Methods

Crystallization of IGF
A poly-glycine model was first generated based on the structure of IRK-0P. Residues 1046 to 1071 (IRK-0P numbering scheme) of the activation loop were omitted in the initial phasing model. The N-terminal and C-terminal domains were then independently refined as rigid domains using the program CNX (Molecular Simulations Inc., San Diego) (31) . Amino acid side chains and the activation loop residues were subsequently built into the model as guided by the electron density. At first, no noncrystallographic symmetry restraints were imposed. Following several rounds of model building and refinement processes, the 2-fold non-crystallographic symmetry operator was refined and employed as a constraint during subsequent refinements; however, no significant improvement was observed in the electron density.
Results and Discussion
Crystals of the apo IGFRK-0P. Among over 2-dozen protein forms we expressed, purified, and screened for crystallization of the human IGFRK, only a 321-residue variant yielded crystals. This construct covered a length of the IGF-1R receptor from residue-944 to residue-1264. The N-terminal amino acid sequence began with ASVN… and the C-terminal sequence ended with …EELD.
The IGFRK-0P kinase remained unphosphorylated upon cell lysis and purification, as evidenced with data from mass spectrometry (see Materials and Methods). Rod shaped crystals of the protein appeared within a week. These crystals were often clustered and always attached to the surface of the crystallization tray. We attempted a number of approaches known to prevent protein crystals sticking to crystallization surfaces to no avail. For these reasons, the crystals used for diffraction suffered physical damage during harvesting, rendering the effective resolution to 2.7Å.
Structure determination. In determining the structure of the apo, unactivated IGFRK, a monomer of the unactivated form of IRK was used as a search model. Rotation function resulted in two solutions that could be related by a 180°-rotation about an axis parallel to the monoclinic 2-fold screw axis. Using these two solutions, operation of the translation function resulted in a significant overlap of the two molecules. Analysis of the self-Patterson revealed a strong peak at u = v = w = 0.5. A dimer was then created using the results from the rotation function and the selfPatterson analyses and was successfully used as the search model. The most significant solutions of the rotation and translation functions led to a correlation coefficient and an R factor of 0.36 and 0.54, respectively. After one round of conjugate gradient minimization, followed by simulated annealing, the 2F o -F c map revealed most of the side-chains for the IGFRK sequence, including a well-ordered activation loop.
Using all data between 20Å-2.7Å resolution, the IGFRK-0P structure was refined to 2.7Å resolution with a crystallographic R-value of 22.9% (see Table 1 ). The refined model consisted of two molecules of the kinase and 212 water molecules. The N-terminal residues 944-951, residues of the kinase insert region 1067-1072 (32) , and the C-terminal residues 1257-1264 were found to be disordered. The model has good geometry (Table 1) as confirmed by PROCHECK (33) . A Ramachandran plot for the two molecules is shown in Figure 1 . The two molecules in the asymmetric unit were virtually identical. Although MgCl 2 was used in crystallization, no Mg 2+ ion was apparent and hence none was modeled into the electron density map. Shown in Figure 2 is the region of the electron density covering residues 1248-1254 of molecule A. Electron density for the molecule B for this segment is equally well defined.
Overall structure. As is seen for other members of the receptor tyrosine kinase family, IGFRK-0P is composed of two domains connected by a single stretch of the polypeptide (the so-called hinge region from residue 1079 to residue 1085).
As shown in Figure 3 , the N-terminal domain is predominantly a twisted β-sheet containing five antiparallel β-strands (β1-β5). Flanking one side of the β-sheet is a single helix known in other tyrosine kinases as αC. The ordered segment of the N-terminus begins with residue Ser952. The C-terminal domain of the kinase comprises eight α-helices (αD, αE, αEF, αF-αJ) and four short β-strands (β7, β8, β10, β11). Lining the ATP binding pocket of the IGFRK-0P and residing at the interface of the two domains are the hinge region (1049-1055), parts of the glycine-rich phosphate binding loop between strands β1 and β2 (975-982), the catalytic loop (1103-1112), and the activation loop (1122-1144).
Overall, the structure of IGFRK-0P closely resembles that of the unactivated IRK-0P (23) . The root-mean-squares deviation for the C α -atoms is 2.5Å between the two structures (not including the disordered residues of kinase insert region). However, the superposition of the separate domains reveals a root-mean-squares deviation of 1Å and 1.3Å for the C-and N-terminal domains, respectively. A comparison of the two proteins is given in Figure 4 . Although the kinase insert region is partly disordered in IGFRK-0P, as seen in the figure the portion that is ordered reveals a different conformation for IGFRK-0P from that observed for IRK-0P, suggesting that the entire insert region may be different between the two kinases. Figure 4 is that the IGFRK-0P structure is in a slightly more "closed" conformation in comparison to that of the IRK-0P. Except for the Nterminal residues from Ser952 to Glu961, the entire Nterminal domain of IGFRK-0P can be envisioned to have rotated as a rigid body, tilting 5° more towards its Cterminal domain. Thus, IGFRK-0P adopts a tighter tertiary configuration.
Domain closure. Also seen in
Conformational changes in the interface.
In addition to the domain closure, the relative orientation of helix αC in IGFRK-0P is different from that in IRK-0P. As shown in Figure 5a , this difference begins at residue Glu1026 (IGFRK numbering) and propagates through the rest of helix αC. As a result, the interactions at the interface of the N-and C-domains are different from those in IRK-0P. Furthermore, the main-chain carbonyl oxygen of Gly1053 in the N-terminal domain of IRK-0P is hydrogen bonded to the side-chain of Lys1126 (IRK numbering) in the Cterminal domain. The residues corresponding to Gly1053 and Lys1126 in IGFRK are Glu1026 and Asn1099 in IRK, respectively. Due to a shorter side-chain length, Asn1099 cannot interact with the main-chain carbonyl of Glu1026. An important consequence of this amino acid change for IGFRK-0P is that the side-chain of its Glu1026, being longer than that of Gly1053 in IRK-0P, is forced to orient away from the N-terminal domain to face the bulk solvent.
There are other conformational differences observed in the N-terminal domain of the two enzymes as a result of primary structure variations. Noticeable are the differences in the β5 strand at position Ile1048 in IGFRK which is occupied by Val1075 in IRK (data not shown). Other residues where primary and tertiary structural differences are observed include Met971 (Leu998 in IRK), Ser972 (Leu999 in IRK) and Val987 (Asn1014 in IRK). Collectively, these differences in the primary structure and their role in stabilizing the inter-domain interactions could be in part responsible for the domain closure observed for IGFRK-0P.
Other changes in inter-domain interactions seen for IGFRK-0P cannot be attributed to alterations in the primary structure. The conformation of the N-terminal stretch from Ser952 to Glu961 adopts a more extended conformation in IGFRK-0P. As a consequence, these residues interact with a different set of residues in its neighborhood. In particular are their interactions with helix αC. Shown in Figure 5b are the position and orientation of helix αC in IGFRK-0P, which is stabilized by hydrogen bonding interactions between the side-chain of Lys1025 and the side-chains of the conserved residues Tyr957 and Asp960. As such, helix αC is likely to have been "pushed" toward the C-domain, effectively bringing the two domains closer towards each other. Due to the close proximity of helix αC and the nucleotide binding loop (the P-loop), the inward positioning of this helix leads to displacement of the P-loop. The P-loop is now tilted towards the ATP binding site. As shown in Figure 5c , the C α atoms of residues 977-982 in IGFRK-0P are shifted by ~3.5Å when compared to the same residues in IRK-0P.
The ATP binding site. The ATP binding pocket lies at the interface of the N-and C-terminal domains and is lined by the residues of the hinge region, the P-loop, and the proximal end of the activation loop (26, 27) . Except for the residues on the proximal end and including the signature DFG motif, the conformation of the activation loop is essentially unchanged in IGFRK-0P from that in IRK-0P. Residue Tyr1131 that is phosphorylated upon activation interacts with the conserved residues Asp1105, Arg1109, and Phe1145, as is seen for the corresponding residues in the IRK-0P structure (23) . Conformation of the other two tyrosines (Tyr1135 and Tyr1136) of IGFRK-0P that are also phosphorylated upon activation remains unaltered as well. As is for IRK-0P, the ATP binding site of IGFRK-0P is inaccessible. The striking difference between the two kinases appears in the conformation of the proximal part of by guest on January 8, 2018
http://www.jbc.org/ Downloaded from the activation loop, residues 1121-1129 of IGFRK-0P and residues 1148-1156 of IRK-0P.
In the unactivated IRK-0P structure, Phe1151 (Phe1124 in IGFRK) resides in the hydrophobic pocket which is otherwise occupied by the adenine ring of the ATP in the ATP-analog bound structure of the activated or mutated form of IRK (24, 25) . This occupancy is not observed in the IGFRK-0P structure. As depicted in the Figure 6a , Phe1124 in IGFRK-0P is swung away from the ATPbinding pocket. In its place is the side-chain of Met1126 inside the hydrophobic pocket. The conformation of this stretch of residues is partly stabilized by an altered orientation of the adjacent P-loop.
The side-chain of Phe1124 is somewhat mobile, however, the other residues in this stretch display a well ordered electron density, as illustrated in Figure 6b . This altered conformation of the activation loop of IGFRK-0P is seen for both molecules in the asymmetric unit.
Overall, the shape of the ATP binding pocket is significantly different between IGFRK-0P and IRK-0P as a result of changes in the relative position of the N-and Cdomains, in the orientation of the P-loop, and in the conformation of the proximal end of the activation loop.
Comparison with activated IGFRK. Crystal structures of the bis-and tri-phosphorylated IGFRK have been reported (26, 27) . Tyr1131 and Tyr1135 are phosphorylated in IGFRK-2P, whereas Y1136 is additionally phosphorylated in IGFRK-3P.
Conformation of the activation loop in IGFRK-3P is significantly different from that observed for the IGFRK-0P. A comparison is given in Figure 7 . Upon activation, the activation loop moves away from the ATP binding pocket, rendering ATP and peptide substrate binding sites accessible. At the same time, the two domains of the kinase are brought closer together to facilitate catalysis (27) , but they are ~7° more "open" than in the case of IRK-3P.
In the structure of IGFRK-2P, the proximal end of the activation loop containing the DFG motif adopts a conformation similar to that observed in the IGFRK-3P structure, enabling ATP binding site accessible (26) . However, the activation loop as a whole possesses a conformation different from that observed in either IGFRK-0P or IGFRK-3P. The relative position of the N-and Cterminal domains of the bisphosphorylated form is intermediate between the unactivated and fully activated form. The overall conformation of this protein is somewhat between the unactivated and fully activated states; it is reminiscent of the Aspl161Ala mutant structure of IRK-0P (25) .
Implications for inhibitor design. Despite the finding that the ATP binding clefts among different protein tyrosine kinases are largely conserved, it has been possible to design kinase specific inhibitors, essentially by exploiting amino acid sequence differences in the ATP binding cleft (34, 35) . Based on the crystal structure of the unactivated IRK (23) , and the amino acid sequence alignment, the residues that line the ATP binding cleft are strictly conserved between IRK and IGFRK. Divergence in the amino acids between these kinases only occurs in regions away from the ATP binding pocket. Thus, developing specific inhibitors against the IGFRK would appear impossible if its tertiary structure in the substrate binding pocket is also identical to that of IRK. For this reason, attempts have been made to design IRK-0P inhibitors against the protein substrate recognition site instead of the ATP binding site (36, 37) . Clearly, the crystal structure of the apo IGFRK-0P reported here reveals discernible structural differences in its ATP binding cleft from that of apo IRK-0P that could be utilized for inhibitor designs.
The repositioned helix αC and a more extended N-terminus leads to a re-oriented P-loop in IGFRK-0P. Together with a conformationally altered activation loop, they present an ATP binding pocket significantly different (Figure 5c ) from that observed in the unactivated IRK. Differences in the amino acid residues distal from the ATP binding site may also play an indirect role in influencing the domain closure, which in turn stabilizes the conformation of the P-loop and the proximal end of the activation loop. For building IGF-1R specific inhibitors targeting the unactivated kinase domain, it might be crucial to include the activation loop as a part of inhibitor binding. The change seen in the proximal end of the activation loop of IGFRK-0P, coupled with its replacement of a protruding Phe1151 (in IRK) by a less bulky Met1126, might offer an avenue for the preparation of inhibitor with differential specificity for IGFRK-0P and IRK-0P.
Another possible region that could be exploited for the design of selective inhibitors is the inter-domain linker region where primary structural differences exit between the two enzymes. In IGFRK, residues Thr1053, Arg1054 and Glu1115 form a contiguous patch adjacent to the ATP binding site (27, 26) . In IRK, Ala1080, His1081 and His1142 replace these residues, respectively.
Dimer formation. As seen in Figure 8 , the two molecules of IGFRK-0P in the asymmetric unit are associated as a dimer with a nearly perfect two-fold symmetry. The two monomers are arranged such that their ATP binding clefts face each other. The ordered N-terminus of one monomer approaches the proximal part of the activation loop, ATP binding pocket, and the catalytic loop of the other monomer. Main-chain atoms of Ser952 of one monomer are only 6 Å away from the side-chain of Phe1124 of the other. In addition, the N-terminus of each monomer interacts with a number of residues of the other monomer.
At low concentration and in solution a dimeric association is not observed for the 321-residue form of IGFRK-0P (unpublished data). Thus, dimer formation of the IGFRK-0P in the crystal may be simply a concentration-dependent phenomenon. However, the two monomers in the asymmetric unit bury between them about 1200Å² of surface area, which is relatively large for a purely crystal packing contact (38) , suggesting a possible functional dimer. In vivo, the cytosolic portion of the β-chains of IGF-1R receptor is a homo dimer. Conceivably, the arrangement of the molecular dimer as seen in our crystal could place the residues of the juxta-membrane region of one monomer in the proximity of the active site of the other to afford blockage of active site access until kinase activation. An auto-inhibitory role of the juxta-membrane region is known for the Eph receptor tyrosine kinase (39) (40) (41) . The tyrosine residues of the juxta-membrane region residues are also known to be phosphorylated during activation (42, 43) , and trans phosphorylation of these residues are conceivable with the dimeric arrangement seen in this crystal structure.
Also intriguing is the observation that the activation loop (in particular Tyr1131) of IGFRK-0P is in close proximity to the ATP binding pocket as well as the catalytic residues within a given monomeric unit, but the activation loop is 28 Å away from the active site of the second monomer. Phosphorylation of the activation loop tyrosine residues has been proposed to occur in trans, based on solution kinetic data. It is not immediately obvious from the present dimeric arrangement of our crystal form of IGFRK-0P how trans auto-phosphorylation of the activation loop tyrosine residues is accomplished, although our data cannot exclude this possibility. 
